Lab study IDs OG treatment for further testing, potential use in IPF
Orcinol glucoside found to reduce lung scarring in mouse, cell models
Written by |
A compound called orcinol glucoside (OG) can reduce lung inflammation and scarring in mouse and cell models of idiopathic pulmonary fibrosis (IPF), according to the findings of a new study, which suggests that OG could prove to be a treatment for the lung condition.
The lab study results indicate that OG reduces the production of a signaling molecule that drives abnormal activity of immune cells called macrophages. The team called for further studies to explore the compound’s potential as an IPF treatment.
“Future research should focus on optimizing OG’s [pharmacological] properties, evaluating its efficacy in clinically relevant models, and exploring combination therapies with existing [IPF treatments] to enhance therapeutic outcomes,” the scientists wrote, adding that “this work opens new avenues for developing precision therapies for IPF.”
The study, “Orcinol glucoside ameliorates pulmonary fibrosis by suppressing hyaluronic acid synthesis and macrophage M2 polarization via targeting hyaluronic acid synthase 2,” was published in the International Journal of Molecular Medicine.
IPF is a chronic disorder characterized by inflammation and scarring, or fibrosis, in the lungs. Multiple types of cells are thought to play a role in driving IPF, including fibroblasts — structural cells that are mainly responsible for producing scar tissue — as well as macrophages.
Macrophages are immune cells that normally play key roles in protecting the body from infections. Data suggest, however, that in IPF, they tend to take on a so-called M2 phenotype, marking a shift in cellular activity that helps promote fibrosis. The molecular mechanisms that drive this abnormal immune cell activation in IPF aren’t fully understood, however.
Investigating the mechanisms that drive IPF
In this study, scientists in China sought to better understand the biological mechanisms that drive IPF. The researchers’ investigation began with a comprehensive analysis of data from IPF patients as well as lab models of the disease.
Across the datasets, the researchers noted that fibroblasts in IPF showed increased levels of an enzyme called hyaluronic acid synthase 2, or HAS2.
The HAS2 enzyme helps cells to produce a molecule called hyaluronic acid, whose high levels correlated with worse lung function and progressive disease in previous studies. In a further series of experiments using lab models, the researchers found that this naturally occurring substance is able to bind to molecular receptors on macrophages — and when it does, it activates macrophages to change their activity to the fibrosis-driving M2 phenotype.
“These findings advance our understanding of IPF [disease development] and provide a preclinical foundation for targeting HAS2 in fibrotic diseases,” the researchers wrote.
Based on their findings, the team hypothesized that blocking the activity of HAS2 might help reduce disease activity in IPF. To explore this idea, the researchers conducted a series of tests looking for compounds that are able to inhibit HAS2. They zeroed in on OG, showing that this compound is able to tightly stick to the enzyme.
The scientists then tested OG in lab models of IPF, including cell models and a mouse model. Across these models, data indicated that OG treatment reduced HAS2 enzyme activity as expected, and in the mouse model this led to a reduction in lung inflammation and fibrosis.
“These results position HAS2 as a promising therapeutic target and OG as a potential candidate for IPF treatment,” the scientists concluded, calling for further research into this approach.
